Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3690

Potential Analysis of Human DNA Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2020-2030

LI_172309
Pages: 120
Jun 2017 | 1612 Views
face gplus_n
Author's : Abha Thakur
Tables: 25
Charts: 35
twit_n pr_n

Potential Analysis Of Human Dna Vaccines Market Overview:

Global Potential Analysis of Human DNA Vaccines Market is expected to account for $3,762 million in 2020 and reach $9,337 million by 2030, by growing at a CAGR of 9.5% during the period, 2020 - 2030.

A DNA vaccine is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity. DNA vaccines have potential advantages over traditional methods, for example, low risk of infection, easy transportation, and stability at room temperature. The potential of global human DNA vaccines market is expected to be rapid, owing to property of DNA vaccines of specific antigen targeting, reduced risk of infection compared to conventional vaccines, and improved stability. Moreover, relative ease of large-scale manufacturing compared to traditional approach and low storage requirement are anticipated to be present few key market opportunities.

According to the World Health Organization, ~18 million deaths occurred due to the unavailability of effective treatment for infectious disease in 2014, which demonstrates the global burden of infectious disease, providing an opportunity for DNA vaccine manufacturers. Moreover, rapid development in the field of molecular biology, immunology, and DNA synthesis is further expected to drive the growth of this market. Factors that may lead to increased demand for DNA vaccines include inefficient drug therapies and increased microbial resistance to existing antimicrobials and antibiotics treatments in the future.

Potential Analysis of Human DNA Vaccines Market Segmentation

Potential analysis of human DNA vaccines market segmentation

Segment Review

The global potential analysis of human DNA vaccines market is analyzed based on forecast scenario, such as rapid growth, moderate growth, and low growth. In the rapid growth scenario, maximum percentage of total population having infectious diseases, HIV, cancer, and other diseases is estimated to be vaccinated in the first year of DNA vaccine.

Geographical Review

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is expected to possess the highest market share, owing to availability of advanced healthcare facilities, followed by Europe, in 2020. However, Asia-Pacific is anticipated to grow at the highest rate in future, due to increase in pool of patient population, rise in geriatric population, and growth in government investments for development of better healthcare facilities and R&D activities.

High Prevalence of Diseases

DNA vaccine involves the administration of DNA components that stimulate protective immunity against a specific infectious agent. The demand for vaccines has increased significantly over the past few years, owing to high incidence of diseases worldwide. These vaccines are highly efficient in preventing infectious diseases, and hence offer opportunity for the market players.

Introduction of DNA vaccines would facility eradication of diseases, such as cancer, hepatitis, HIV, and others. In addition, vaccines are essentially recommended for travelers as they are at a high risk of exposure to various diseases. For instance, travelers are advised to be vaccinated against cholera, hepatitis, meningococcal diseases, Japanese encephalitis, typhoid fever, yellow fever, rabies, polio, and tick-borne encephalitis while traveling. The incidence of aforementioned diseases in selective travel destinations has increased the need for DNA vaccines across different geographies. Furthermore, certain diseases require routine vaccinations, such as cholera; dengue; diphtheria, tetanus, pertussis (DTP), haemophilus influenza type B; hepatitis A; hepatitis B; and human papilloma virus. Furthermore, increase in incidence of pneumococcal diseases and influenza boosts the demand for DNA vaccines. In addition, DNA vaccines provide both humoral and cell-mediated immunity, thus having a wide application area.

The major selected clinical targets for DNA vaccines are influenza, human papillomavirus, and HIV. According to the World Health Organization, cervical cancer (caused due to HPV) is the third leading cause of death worldwide. Preventive HPV vaccines, such as Gardasil (Merck) and Cervarix (GlaxoSmithKline) have been developed, in 2006 and 2009, respectively. But the impact of these vaccines is slow due to high economic burden and high incidence of HPV. Thus, DNA vaccines can provide strong cellular response, and hence provide faster immunization against HPV. Several DNA vaccine clinical trials have been recently completed or are currently ongoing, such as ZYC101 (Eisai Pharmaceuticals) has completed phase I trial. HPV-16 and HPV-18 E6/E7 are being evaluated in a phase I clinical trial (Inovio Pharmaceuticals).

The key players profiled in the report include Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

Key Market Benefits of the Report:

  • It offers an in-depth study of the global potential market for human DNA vaccines market based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030
  • It provides potential analysis of opportunities to understand different aspects of the human DNA vaccines that are currently under various phases of clinical trials, along with the variants that would gain prominence in the future
  • It covers vaccine pipeline products against DNA, which are under various clinical stages
  • It profiles key market players and their strategies to understand the various technologies adopted by them to manufacture DNA vaccines

Potential Analysis of Human DNA Vaccines Market Key Segment:

By Forecast Scenario Analysis

  • Rapid Growth Scenario
  • Moderate Growth Scenario
  • Low Growth Scenario

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES

Chapter: 4 FORECAST SCENARIO ANALYSIS OF HUMAN DNA VACCINES MARKET

4.1. OVERVIEW

4.1.1. Market size & forecast

4.1.1.1. Rapid growth scenario
4.1.1.2. Moderate growth scenario
4.1.1.3. Low growth scenario

Chapter: 5 GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key opportunities
5.2.2. Market size & forecast

5.3. EUROPE

5.3.1. Key opportunities
5.3.2. Market size & forecast

5.4. ASIA-PACIFIC

5.4.1. Key opportunities
5.4.2. Market size & forecast

5.5. LAMEA

5.5.1. Key opportunities
5.5.2. Market size & forecast

Chapter: 6 COMPANY PROFILES

6.1. INOVIO PHARMACEUTICALS, INC.

6.1.1. Overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Product pipeline
6.1.6. Research funding
6.1.7. Key strategic developments

6.2. GENEONE LIFE SCIENCE INC.

6.2.1. Overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Product pipeline
6.2.6. Research funding
6.2.7. Key strategic developments

6.3. MEDIMMUNE

6.3.1. Overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Product pipeline
6.3.6. Research funding
6.3.7. Key strategic developments

6.4. IMMUNOMIC THERAPEUTICS, INC.

6.4.1. Overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Product pipeline
6.4.6. Research funding
6.4.7. Strategic moves and developments

6.5. ASTELLAS PHARMA, INC.

6.5.1. Overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Product pipeline
6.5.6. Research fuding
6.5.7. Strategic moves and developments

6.6. PHAROS BIOLOGICALS

6.6.1. Overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Product pipeline
6.6.6. Research funding
6.6.7. Strategic moves and developments

6.7. SANOFI S.A.

6.7.1. Overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Product pipeline
6.7.6. Research funding
6.7.7. Strategic moves and developments

6.8. F. HOFFMANN-LA ROCHE AG

6.8.1. Overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Product pipeline
6.8.6. Research funding
6.8.7. Strategic moves and developments

6.9. CUREVAC

6.9.1. Overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Product pipeline
6.9.6. Research fuding
6.9.7. Strategic moves and developments

6.10. BOEHRINGER INGELHEIM GMBH

6.10.1. Overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Product pipeline
6.10.6. Research funding
6.10.7. Strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 2. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 3. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 4. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 5. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 6. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 7. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 8. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 9. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 10. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 11. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 12. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 13. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 14. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 15. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
TABLE 16. INOVIO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 17. GENEONE LIFE SCIENCE INC.: COMPANY SNAPSHOT
TABLE 18. MEDIMMUNE: COMPANY SNAPSHOT
TABLE 19. IMMUNOMIC THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 20. ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT
TABLE 21. PHAROS BIOLOGICALS: COMPANY SNAPSHOT
TABLE 22. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 23. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 24. CUREVAC: COMPANY SNAPSHOT
TABLE 25. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, 2020-2030
FIGURE 2. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY, 2020-2030
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 6. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 7. GLOBAL RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 8. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 9. GLOBAL MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 10. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 11. GLOBAL LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 12. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 13. NORTH AMERICA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 14. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 15. NORTH AMERICA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 16. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 17. NORTH AMERICA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 18. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 19. EUROPE RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 20. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 21. EUROPE MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 22. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 23. EUROPE LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 24. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 25. ASIA-PACIFIC RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 26. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 27. ASIA-PACIFIC MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 28. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 29. ASIA-PACIFIC LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 30. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 31. LAMEA RAPID GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 32. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 33. LAMEA MODERATE GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020
FIGURE 34. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET, 2020-2030 ($MILLION)
FIGURE 35. LAMEA LOW GROWTH SCENARIO OF POTENTIAL HUMAN DNA VACCINES MARKET SHARE (%), 2020

 

A DNA vaccine consists of genetically engineered DNA of the antigen and is administered in the body, which leads to antibody production. DNA vaccines are safer and more stable than traditional vaccines. Selected clinical targets for DNA vaccines are influenza, HPV, and HIV. Since the discovery of DNA vaccines, i.e., 20 years ago, intensive R&D activities have been done to understand the basic biology and working of DNA vaccines. Numerous vaccines are under different phases of clinical trials such as VGX-3100 in Phase II trial, INO-3112 in phase I trial, and others.

DNA vaccines are advantageous as they are economical to produce as compared to recombinant protein vaccines, and easier to transport, use, and store. DNA vaccines are highly specific for diseases and have a faster mode of action than traditional vaccines.

North America is expected to dominate the DNA vaccines market, owing to high incidence of infectious diseases such as cancer, HIV, and others.

Major companies involved operating in this market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Potential Analysis of Human DNA Vaccines Market- Global Opportunity Analysis and Industry Forecast, 2020-2030

  • Online Only
  • $3690
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4099
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $4999
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6004
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8373
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts